eSupervisor Detail

About me

PhD molecular biologist with 6+ yrs cancer research and 5+ yrs teaching experience at Delhi University's ACBR. Specializes in glioblastoma chemoresistance mechanisms — epigenetics, DUBs, RNA-binding proteins. 6 peer-reviewed papers, 1 granted patent, CSIR-NET qualified. Skilled in PCR, cloning, Western blotting, IHC, flow cytometry, and in vivo tumor models. Seeking Assistant Professor, postdoctoral, or industry R&D roles in cancer biology/translational oncology.

Interests: My research centers on understanding the molecular basis of chemotherapy resistance in glioblastoma (GBM), one of the most treatment-refractory cancers due to its intrinsic and acquired resistance to standard therapies like Temozolomide. I am particularly interested in how epigenetic regulation — specifically MGMT promoter methylation — interacts with deubiquitinating enzymes such as USP5 to drive drug resistance, and how targeting this axis could restore chemosensitivity in resistant tumors. A second thread of my work explores post-transcriptional regulation in glioma survival, including how isoform switching in RNA-binding proteins like hnRNPA1 and SETD5-mediated regulation contribute to resistance against both Temozolomide and TRAIL-induced apoptosis. I am interested in extending this work using genomic and proteomic approaches to identify additional resistance-conferring proteins and pathways that could serve as therapeutic targets or biomarkers for treatment stratification. Going forward, I aim to build an independent research program that bridges mechanistic cancer biology with translational application — combining cell-based models, in vivo tumor systems, and natural-compound-derived therapeutics (building on my patented work with Withania somnifera) to develop resistance-reversal strategies for glioma and other treatment-resistant cancers. I am also broadly interested in the role of the tumor microenvironment and epigenetic plasticity in mediating drug tolerance, and would welcome opportunities to collaborate across genomics, structural biology, and pharmacology to advance this work.